Wugen is dedicated to developing off-the-shelf cell therapies for treatment of cancer
These cell therapy drugs originate from healthy donors and are amplified in order to enhance cancer cell elimination. Our Immuno-Oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML), multiple myeloma (MM) and T-cell malignancies.
At Wugen, we are focused on off-the-shelf:
- NK cell therapies targeting solid tumors, AML, and MM
- CAR-T targeting T-cell malignancies
- CAR-T targeting AML blasts while avoiding healthy stem cells
Our issued and pending patents support and protect a strong pipeline of cancer therapies offered to patients with high risk cancers.